Vectus Biosystems Ltd Total Assets
Vectus Biosystems Ltd total assets. Based on the latest financial reports, Vectus Biosystems Ltd (VBS) holds total assets worth AU$782.66K AUD (≈ $553.78K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of Vectus Biosystems Ltd for the company's overall valuation and market capitalisation.
Total Assets of Vectus Biosystems Ltd (2012–2025)
Total assets of Vectus Biosystems Ltd from 2012 to 2025. This chart illustrates how Vectus Biosystems Ltd's total assets have evolved over time, based on quarterly financial data. See Vectus Biosystems Ltd stock quote for real-time trading data and today's change.
Vectus Biosystems Ltd - Asset Composition Analysis
Vectus Biosystems Ltd Total Assets Breakdown (June 2025)
Vectus Biosystems Ltd total assets breakdown as of June 2025. Vectus Biosystems Ltd's total assets of AU$782.66K consist of 99.5% current assets and 0.5% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 32.1% |
| Accounts Receivable | AU$437.57K | 55.9% |
| Inventory | AU$978.00 | 0.1% |
| Property, Plant & Equipment | AU$4.22K | 0.5% |
| Intangible Assets | AU$0.00 | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Vectus Biosystems Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Vectus Biosystems Ltd short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vectus Biosystems Ltd's current assets represent 99.5% of total assets in 2025, an increase from 58.8% in 2012.
- Cash Position: Cash and equivalents constituted 32.1% of total assets in 2025, down from 50.7% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 55.9% of total assets.
Vectus Biosystems Ltd Competitors by Total Assets
Key competitors of Vectus Biosystems Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Vectus Biosystems Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 3.45 | 2.02 |
| Quick Ratio | 0.93 | 3.45 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 1.86 |
| Working Capital | AU$-57.45K | AU$1.31 Million | AU$1.47 Million |
Vectus Biosystems Ltd - Advanced Valuation Insights
This section examines the relationship between Vectus Biosystems Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.66 |
| Latest Market Cap to Assets Ratio | 3.38 |
| Asset Growth Rate (YoY) | -61.4% |
| Total Assets | AU$782.66K |
| Market Capitalization | $2.65 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Vectus Biosystems Ltd's assets at a significant premium (3.38x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Vectus Biosystems Ltd's assets decreased by 61.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vectus Biosystems Ltd (2012–2025)
The table below shows the annual total assets of Vectus Biosystems Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$782.66K ≈ $553.78K |
-61.36% |
| 2024-06-30 | AU$2.03 Million ≈ $1.43 Million |
-56.25% |
| 2023-06-30 | AU$4.63 Million ≈ $3.28 Million |
+17.62% |
| 2022-06-30 | AU$3.94 Million ≈ $2.79 Million |
-43.60% |
| 2021-06-30 | AU$6.98 Million ≈ $4.94 Million |
+132.77% |
| 2020-06-30 | AU$3.00 Million ≈ $2.12 Million |
+1444.61% |
| 2019-06-30 | AU$194.11K ≈ $137.34K |
-1.11% |
| 2018-06-30 | AU$196.28K ≈ $138.88K |
-72.76% |
| 2017-06-30 | AU$720.55K ≈ $509.84K |
-84.62% |
| 2016-06-30 | AU$4.68 Million ≈ $3.31 Million |
-60.06% |
| 2015-06-30 | AU$11.73 Million ≈ $8.30 Million |
+1533.55% |
| 2014-06-30 | AU$717.98K ≈ $508.02K |
-51.88% |
| 2013-06-30 | AU$1.49 Million ≈ $1.06 Million |
+121.75% |
| 2012-06-30 | AU$672.80K ≈ $476.05K |
-- |
About Vectus Biosystems Ltd
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue t… Read more